Benzinga
01 Oct 2026, 18:31 UTC · 23h ago
Verdict
Headline takes no side. We score ABBV +0.60 across three claims — strongly bullish.
+0.60strongly bullish
More positive than 77% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Ontunisertib achieved a 3% annualized disease-related event rate in a 48-week Phase 2a extension trial for fibrostenotic Crohn’s disease.
Newpublished October 1, 2026
So whatThe 3% rate represents an ~87% reduction compared to the lower end (23%) of current advanced therapy benchmarks.
More positive than 99% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
By Week 48 of the extension study, 97% of evaluable patients achieved clinical remission based on Crohn’s Disease Activity Index scores.
Newpublished October 1, 2026
So whatHigh remission rates in the extension phase increase the probability of success for the upcoming Phase 2b trial.
More positive than 93% of claims this week
Agomab completed regulatory filings for the NOV-ERA global Phase 2b trial involving approximately 320 patients.
Newpublished October 1, 2026
So whatEnrollment for the three dose levels will be the primary catalyst for the stock throughout the next 12-18 months.
More positive than 79% of claims this week
Which stocks this story touches
More positive than 77% of ticker scores this week
Positive late-stage study results for Skyrizi bolster its competitive positioning in the Crohn's market.
More negative than 70% of ticker scores this week
Despite positive Phase 2a clinical data, the stock experienced a significant price drop of nearly 18%.
More negative than 64% of ticker scores this week
Mentioned as a competitor facing increased pressure from AbbVie's strong clinical results.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
11h ago
−0.4%
Price flat so far
$260.62 vs $261.59 close before publication (Sep 30) · not market-adjusted
ABBV chart →
